Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Citigroup Downgrades Allstate to Neutral, Raises Price Target to $142

Citigroup analyst Suneet Kamath downgrades Allstate (NYSE:ALL) from Buy to Neutral and raises the price target from $135 to $142.
byBenzinga Newsdesk
June 3, 2021
1 minute read
Total
0
Shares
0
0
0
0
0
0

Citigroup analyst Suneet Kamath downgrades Allstate (NYSE:ALL) from Buy to Neutral and raises the price target from $135 to $142.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Immuron Announced in a Publication from the Hebrew University Hadassah Medical Center ‘Augmented Antiviral T Cell Immunity by Oral Administration of Imm-124e in Preclinical Models and a Phase I/iia Clinical Trial: a Method for the Prevention and Treatm…

By Charles Gross
Today, 7:08 AM
Immuron Limited (NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutic products for the prevention and treatment of gut pathogens, is pleased to notify shareholders of a recent publication describing the potential antiviral benefits of IMM-124E in a mouse model

IMRN